Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-MAA Radiation Dose Study for HCC Patients (MAApping)
NCT05848947Phase 4Completed
- Sponsor
- Sirtex
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of technetium Tc 99m macroaggregated albumin in hepatocellular carcinoma (HCC), sponsored by Sirtex. Primary endpoints: Mean Absorbed Dose for the Whole Body, Mean Absorbed Dose for Critical Non-liver Organs and 3 more. Started Apr 2023; status: completed.
02
Drugs
technetium Tc 99m macroaggregated albumin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05848947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848947.